Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. - Wikidata - awgldk - TriplyDB

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

http://www.wikidata.org/entity/Q43032187

about

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials Ribavirin: Past, present and future Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Gene expression and hepatitis C virus infection Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice Optimizing the dose and duration of therapy for chronic hepatitis C.Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Peginterferon and ribavirin treatment for hepatitis C virus infection Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Cost-effectiveness of screening for hepatitis C in Canada.Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.Impact of ribavirin dose on retreatment of chronic hepatitis C patients A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm.The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA.Ribavirin in the treatment of chronic hepatitis C.Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.Optimizing the treatment of chronic viral hepatitis C.25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C Hepatitis C variability, patterns of resistance, and impact on therapy DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.

P2860

Q26745895-612FB3AE-47F8-462A-AED1-5E2226EAF019 Q26775002-CBAD93EB-5354-4F7E-9D72-C52BCEB36D8D Q27480933-7DCCF80E-DB40-4688-B3AC-19AB10E4E39A Q27487942-5D5442F4-A9B3-4C2D-9640-42CD70F3E8E7 Q27488345-9A315A11-1CF1-4E90-9E34-53980AD192A6 Q27488563-E71B1873-8096-45B0-AE33-B701FEBE84AC Q27489596-4B111907-4397-4A2A-A87B-B564063BE007 Q27490447-0E067798-AEBF-48D2-9914-E57B138FE120 Q33855483-18DA0A86-E77D-401C-9A84-DC2BE13C6DCD Q33899320-4940EE27-575B-4D80-A948-41D6E5EC7612 Q33906899-2C7135BB-A268-47C7-A694-D0A6C44A4AE3 Q33956478-F89852D6-E892-4B43-98E0-4ECDB81AD47A Q34334776-B9807D89-3928-4450-8459-5BE25A1EEDCB Q34409020-28DF3FDC-F35F-4450-B685-DD4D86C54D32 Q34521371-6EE46327-197C-4AD8-9309-14504ECF1D63 Q34626479-A3F02A5A-6EC1-4D75-B077-36838A4C477E Q34996746-B3F62EA0-0B68-4D60-B72A-AE918085BC61 Q35088460-61A8180D-B1B2-4DD8-8F15-DF1278EB21D0 Q35893868-8F7D4AE5-77B0-4EBF-B77F-9866CF98C39A Q36049907-0C371897-D15C-4910-BDA0-AA6B5926CE56 Q36306694-2C207436-9D3D-471B-9F93-A2C3F0A6C5FA Q36736241-ACEFF819-1B89-45BB-8E6E-31E14F4B1276 Q36884431-5A47E026-4745-4611-B7B1-C7D15E74A88C Q37195248-6C000F88-8351-4009-B320-B78B2C3AFEEC Q37627878-64ED685F-F6AA-4E18-9002-F97871B3E7FE Q37636095-8FF90F43-ADC1-45A2-A146-BA2E73FA47A5 Q37741812-228185A6-A952-475C-AEC9-A0B08F3C8ACD Q37765571-FF96D4B3-1896-4DDF-996B-EC0E15C3D385 Q37772959-841AB51C-FEB8-46B8-882B-27B24E307CF7 Q37846232-35581A84-9C50-44C0-AB51-EC7069EDAAE4 Q37939247-FD32B9DF-D88F-4090-BDF4-EA766B3C5E92 Q37972768-39AB219F-D961-4161-BEE3-6A2C33640F37 Q37972769-2FDE2070-9F40-46D4-945B-68B5163DD7E8 Q37990840-28D3163F-5458-4788-A500-80F576E8B9ED Q38073656-DE8C5E61-FA1F-407E-8391-AF90C1969B5F Q38530211-8EAA57FC-F5BB-40D1-A18D-EE592FC9877F Q38848491-7E03A1A6-34D1-4F30-98F7-257D2C91256C Q38915259-6AE24B42-B356-4551-934D-EF337A7ED7EE Q39576325-3139C9C5-8461-48BD-91FA-2F296EEE2A6E Q39749560-CB81641B-4F4D-4424-B68B-A8B19E4FBB7C

P2860

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

http://www.wikidata.org/entity/Q43032187

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.

@en

Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.

@nl

type

label

Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.

@en

Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.

@nl

prefLabel

Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.

@en

Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.

@nl

P1433

Q43032187-BC10C0A0-2DE8-4D24-ABC6-8AC0C62DC823

P1476

Q43032187-F618AF4B-5B8C-47EC-869E-169CB8042A51

P2093

Q43032187-06356FF8-0467-4CF1-8B39-A4AA1E5C5FE0

Q43032187-0AD24329-1CD6-4DB0-8047-DED95A34F376

Q43032187-192EADDE-CEBF-4582-B525-F684396314BE

Q43032187-1A106E40-BFE6-4587-AEF2-BF8685E13B0C

Q43032187-2E9EC462-FF50-47E1-AC14-42B14FCF77A5

Q43032187-416E929B-1696-431F-BCA0-C75F0D9C03CF

Q43032187-46BDAC66-FF21-4FCC-91C7-37BB8DC0768E

Q43032187-4D161C12-E456-4D1A-AA63-241D5900DACB

Q43032187-52552C54-A8A5-422B-9239-09FDFC8EA735

Q43032187-7DFE6C42-5854-4DEC-A771-C3B7DADC24E8

P304

Q43032187-458DAECF-7360-47DA-810A-E9B63D3D67EE

P31

Q43032187-73C4346C-6BFB-4548-BC82-D9C4CA7E4E9D

P356

Q43032187-C98F9E78-486B-4088-AC8E-BB6B92514AED

P407

Q43032187-358C679D-3553-4B9C-A10F-FCDFC7D51A4D

P433

Q43032187-B97DF9DA-E989-45A3-A1A3-FDD606C90C58

P478

Q43032187-0813549F-4FB2-454E-B144-98BFD8FF3D6E

P50

Q43032187-61A6AE73-FB2B-42D7-9FF5-EC5FD553B314

Q43032187-861E4A56-9119-4C5F-B94D-639F1D72F21F

Q43032187-CCFC7F60-F601-4236-B2DE-D3F40C91895C

Q43032187-CEAC44BB-282F-4D0A-A5AF-E5EA4E39465B

P577

Q43032187-8E1C1BA9-5E61-4143-8B25-EAE3003A9112

P698

Q43032187-701EF9F5-9959-4774-B269-598E6E440D81

P356

J.GASTRO.2006.07.022

P1433

Gastroenterology

P1476

Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.

@en

P2093

Albert Tran

http://www.w3.org/2001/XMLSchema#string

Christophe Hézode

http://www.w3.org/2001/XMLSchema#string

Christophe Renou

http://www.w3.org/2001/XMLSchema#string

Denis Ouzan

http://www.w3.org/2001/XMLSchema#string

François Montestruc

http://www.w3.org/2001/XMLSchema#string

Hervé Desmorat

http://www.w3.org/2001/XMLSchema#string

Isabelle Lonjon-Domanec

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Bronowicki

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Zarski

http://www.w3.org/2001/XMLSchema#string

Juliette Foucher

http://www.w3.org/2001/XMLSchema#string

P304

1040-1048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2006.07.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Michel Pawlotsky

Christophe Hézode

Magali Bouvier-Alias

Jean-Pierre Zarski

P577

2006-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17030174

http://www.w3.org/2001/XMLSchema#string